Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply

Documents similaires

• A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
  par: Maral Amangurbanova, et autres
  Publié: (2024)
• Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
  par: Federica Tavaglione, et autres
  Publié: (2025)
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  par: Donghee Kim, et autres
  Publié: (2025)
• Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
  par: Luis Antonio Díaz, et autres
  Publié: (2025)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
  par: Kaleb Tesfai, et autres
  Publié: (2025)